title: Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.
abstract: Cancer cell metabolism responsive to androgen deprivation therapy (ADT) may be involved in the development and progression of prostate cancer and the ultimate failure of androgen-deprivation therapy. To investigate the metabolism regulation effects on androgen-independent growth of prostate cancer, an established LNCaP-s cell model that resembles the clinical scenario of castration-resistant prostate cancer (CRPC), was used in this current study. This cell line was cultured from androgen-sensitive LNCaP parental cells, in an androgen-reduced condition, resembling clinical androgen deprivation therapy. To assess the effects of smsDX on the invasiveness of prostate cancer cells we used wound healing assay and Matrigel™ invasion assay. We evaluated differentially expressed proteins of the parental LNCaP cells and LNCaP-s cells after ADT by means of two-dimensional gel electrophoresis (2-DE) followed by MALDI-TOF mass spectrometric analysis. The covered area in the wound and the number of cells invading through a Matrigel chamber were significantly smaller for cells treated with smsDX than they were for control cells treated with vehicle. 56 proteins were found differentially expressed in LNCaP-s cells compared to LNCaP cells, majority of them were down-regulated after ADT treatment. 104 proteins of LNCaP cells and 86 in LNCaP-s cells, separately, were found differentially expressed after treatment with smsDX, When we explored these protein functions within the website UniProtKB/Swiss-Prot, surprisingly, most of the proteins were found to be involved in the cellular metabolism and mitochondrial function regulation. LNCaP-s as potential metastatic androgen-independent cancer cells, its metabolism and mitochondrial functions could be altered by a new somatostatin derivative smsDX, the smsDX regulatory effects on metabolism in LNCaP-s deliver more therapeutic information with the treatment of CRPC.
authors: Department of Urology, Qilu Hospital, Shandong University, Jinan, China.
authors: Lei
authors: L
authors: Yan
authors: Department of Urology, Qilu Hospital, Shandong University, Jinan, China.
authors: Zhaoquan
authors: Z
authors: Xing
authors: Department of Urology, Qilu Hospital, Shandong University, Jinan, China.
authors: Zhaoxin
authors: Z
authors: Guo
authors: Department of Urology, Qilu Hospital, Shandong University, Jinan, China.
authors: Zhiqing
authors: Z
authors: Fang
authors: Department of Urology, Qilu Hospital, Shandong University, Jinan, China.
authors: Wei
authors: W
authors: Jiao
authors: Aging and Health Center, School of Nursing, Shandong University, Jinan, China.
authors: Xiaoyu
authors: X
authors: Guo
authors: Department of Urology, Qilu Hospital, Shandong University, Jinan, China.
authors: Zhonghua
authors: Z
authors: Xu
authors: Department of Obstetrics and Gynecology, Jinan Central Hospital, Shandong University, Jinan, China.
authors: Zhenghui
authors: Z
authors: Fang
authors: Department of Urology, Qilu Hospital, Shandong University, Jinan, China.|Aging and Health Center, School of Nursing, Shandong University, Jinan, China.
authors: Zhaoxu
authors: Z
authors: Liu
mesh_terms: D000728:Androgens / Q000378:metabolism*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D008297:Male; D053858:Metabolic Networks and Pathways / Q000187:drug effects*; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D040901:Proteomics; D011944:Receptors, Androgen / Q000378:metabolism; D013004:Somatostatin / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000728:Androgens; D011944:Receptors, Androgen; D013004:Somatostatin